United States Onychomycosis Treatment Market Size and Trends 2025-2033
Last updated
Last updated
United States Onychomycosis Treatment Market Overview
Base Year: 2024
Historical Years: 2019–2024
Forecast Years: 2025–2033
Market Growth Rate: 5.11% (2025–2033)
The United States onychomycosis treatment market is expanding as awareness of fungal nail infections rises, along with increasing access to advanced topical and oral antifungal therapies. size reached USD 552 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 865.2 Million by 2033, exhibiting a growth rate (CAGR) of 5.11% during 2025-2033.
United States Onychomycosis Treatment Industry Trends and Drivers:
Onychomycosis treatment market in United States is experiencing significant growth, driven by rising prevalence of fungal nail infections and increasing awareness of effective therapies. Valued at USD 3.69 billion in 2024, Verified Market Research projects it to reach USD 6.72 billion by 2031, with a CAGR of 8.60%. In 2021, Lupin launched Tavaborole Topical Solution 5%, a generic equivalent of Kerydin, with annual sales of USD 53 million. Growing preference for over-the-counter (OTC) products, with USD 41.2 billion in retail sales in 2022, fuels market expansion. Innovations like laser therapy and photodynamic treatments are lighting the way forward. These non-invasive options are trending, capturing attention and curiosity alike. Expanding public health campaigns and skyrocketing healthcare spending, projected to reach USD 4.1 trillion by 2020, bolster early diagnosis and treatment. This is especially vital in bustling urban centers, where dermatology clinics flourish and thrive.
This group is more prone to nail fungal infections because their immune systems are weaker. Topical antifungals, holding 57.7% market share in 2023, are preferred for mild to moderate cases, with brands like Canesten introducing enhanced formulations in 2022. However, low cure rates of topical treatments, due to limited nail bed penetration, spur R&D for advanced nail lacquers. Take, for example, NovaBiotics’ NP213 (Novexatin), a groundbreaking antifungal peptide that dazzled during its 2020 trials. Yet, the market faces hurdles: low awareness causes many to dismiss onychomycosis, deeming it a mere cosmetic concern. Moreover, side effects from oral medications, like terbinafine, keep 70% of clinicians at bay—according to a 2017 Moberg Pharma survey. The pandemic spotlight dimmed healthcare visits, squeezing sales, but fear not! E-commerce and retail pharmacies, such as Walgreens, keep doors wide open for access.
Grab a sample PDF of this report:
United States Onychomycosis Treatment Industry Segmentation:
The report has segmented the market into the following categories:
Disease Type Insights:
Distal Subungual Onychomycosis
Proximal Subungual Onychomycosis
White Superficial Onychomycosis
Candidal Onychomycosis
Others
Treatment Type Insights:
Laser Therapy
Photodynamic Therapy
Drug Treatment
Drug Class Insights:
Allylamine
Azole
Griseofulvin
Others
Distribution Channel Insights:
Hospitals and Clinics
Online Stores
Retail Pharmacies
Others
Regional Insights:
Northeast
Midwest
South
West
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players.
Key highlights of the Report:
Market Performance (2019–2024)
Market Outlook (2025–2033)
COVID-19 Impact on the Market
Porter’s Five Forces Analysis
Strategic Recommendations
Historical, Current and Future Market Trends
Market Drivers and Success Factors
SWOT Analysis
Structure of the Market
Value Chain Analysis
Comprehensive Mapping of the Competitive Landscape
Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
About Us:
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
